Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06137755 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 19, 2024 (before its estimated March 21, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. 3 versions Re-verified since Nov 19, 2023, no change to tracked fieldsv3-v5
  2. Study title expanded, about 2 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.
Trial Details
NCT Number NCT06137755
Lead Sponsor Aribio Lab Co., Ltd.
Conditions
(from sponsor)		 Vaccine-Preventable Diseases, Herpes Zoster
Related terms Herpes Zoster, Vaccine-Preventable Diseases
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov